What Femozol treats: Main Uses and Benefits

Femozol (Letrozole) is commonly used to provide targeted therapeutic support by addressing the underlying hormonal environment that drives specific types of malignancy, rather than treating acute, physical symptoms. Its use is generally limited to certain cancers that may be reliant on estrogen for growth.

The medication is relevant for easing challenging symptomatic phases across different stages of hormone-receptor positive breast cancer. This includes its application in adjuvant treatment (following initial definitive therapy), extended adjuvant management (after an initial course of treatment), and as first-line systemic therapy for advanced, metastatic disease.

Management of Therapeutic Domains

This treatment is considered relevant for long-term disease management in postmenopausal women who have successfully completed initial treatments. It is applied to reduce the potential for the cancer to return. The key benefit is a sustained protective effect that contributes to prolonging the interval a patient remains without signs of recurrence and supports a lower overall disease burden in the years following definitive therapy. The focus is generally on managing the primary disease factor:

“The therapy is relevant for easing discomfort related to the primary hormonal influence, supporting the patient during a critical phase of disease management.”

When used for advanced cancer, Femozol assists with managing the speed of disease progression and may assist in easing the overall systemic burden related to the malignancy.

---

Quick Fact: Relief for Malignancy Control
Primary Indication: Hormone-receptor positive breast cancer
Main Benefit: Helps manage the risk of recurrence during the adjuvant phase
Symptom Focus: Supports the management of systemic imbalance

---

Official Population Eligibility Rules

The eligibility for Femozol (Letrozole) is strictly governed by regulatory status, primarily restricting use to certain adult populations based on hormonal status and organ function.

Absolute Contraindications

The medicine is contraindicated and must not be used by several groups, as defined in official labeling:

• Premenopausal Endocrine Status: The drug is strictly indicated only for women who have reached postmenopausal status.
• Pregnancy and Lactation: Use is prohibited during pregnancy and breastfeeding.
• Hypersensitivity: Patients with known allergy or hypersensitivity to Letrozole or any product excipients.

Restrictions and Conditional Use

Use is restricted or requires special consideration in patients with organ dysfunction:

• Severe Hepatic Impairment (Child-Pugh Class C) requires close supervision due to significantly increased drug exposure.
• Severe Renal Impairment (Creatinine Clearance < 10 mL/min) has insufficient data, and the risk must be carefully weighed by a physician.
• Mild-to-moderate hepatic or renal impairment does not typically require an eligibility restriction.

Age-Related Eligibility

Femozol is not recommended for use in children and adolescents (up to 18 years) as safety and efficacy have not been formally established in this age group. Older adults (geriatric patients) generally do not require a specific adjustment based on age alone.

Femozol (letrozole) is an aromatase inhibitor, and its primary therapeutic effect is to significantly lower the body’s circulating estrogen levels. Interactions with other medicines are mostly centered on maintaining this anti-estrogenic activity.

Contraindicated and Restricted Combinations

Femozol should not be given concurrently with any estrogens or estrogen-containing therapies, including hormone replacement therapy (HRT) or estrogen-containing supplements. This is due to a pharmacodynamic antagonism, where the estrogen products may directly counteract the estrogen-lowering effect of Femozol, reducing its effectiveness.

The co-administration of Femozol and tamoxifen is also a contraindicated combination. Tamoxifen, an anti-estrogen therapy, has been shown to decrease the plasma levels of letrozole by an unspecified interaction mechanism, potentially compromising treatment efficacy. This prohibition applies only to concurrent use; the therapeutic effect of Femozol is generally not impaired when administered after the completion of tamoxifen therapy.

Other Documented Interactions

Clinical studies have demonstrated no clinically significant pharmacokinetic interaction when Femozol is co-administered with cimetidine or warfarin. Letrozole is primarily metabolized by the CYP2A6 and CYP3A4 enzymes; however, no dose adjustment is routinely required based on its interaction profile with these commonly used medicines. Patients should inform their healthcare providers of all medicines, vitamins, or herbal products they are taking.

How Femozol Works

Femozol's mechanism involves the selective inhibition of the aromatase enzyme (CYP19A1) , which is the biological target responsible for converting androgen hormones (like androstenedione and testosterone) into estrogen (estradiol and estrone). The drug binds competitively to the enzyme's active site, blocking its catalytic function.

This blocking action effectively suppresses estrogen production in peripheral tissues, such as fat and muscle, and to a lesser extent, within the ovaries. This results in a profound reduction in the levels of circulating estrogen throughout the body, influencing humoral signaling.

The resulting low estrogen state indirectly influences the Hypothalamic-Pituitary-Ovarian (HPO) axis. The pituitary gland detects the reduced estrogen feedback, leading to an increased release of gonadotropins like FSH and LH. This alteration in regulatory feedback results in the stimulation of ovarian follicular activity in pre-menopausal individuals.

How to Use Femozol

Femozol (Letrozole) is administered as a single-component, 2.5 mg tablet intended for oral intake, consistent with established protocols for anti-hormone therapy. The general principle of administration is based on a fixed, once-daily schedule to maintain consistent drug levels.

---

Official Administration Schedule

The standard dosage for all approved indications in adult women is 2.5 mg taken once daily.

Category	Official Usage Instruction
Route of Administration	Oral
Dosing Schedule	2.5 mg once daily
Timing in Relation to Meals	Can be taken with or without food
Tablet Intake	Tablet must be swallowed whole

---

Duration and Population Constraints

The required duration of treatment is highly dependent on the specific clinical context. For use in the adjuvant setting, treatment typically continues for up to five years, or for extended adjuvant use, a duration pattern of up to five years may follow initial therapy. For advanced or metastatic disease, treatment is continued until documented disease progression.

Dose adjustments are specified for certain populations. The standard 2.5 mg daily dose requires no modification for older adults or patients with mild-to-moderate renal impairment. However, for patients diagnosed with severe hepatic impairment (Child-Pugh C), the regimen is adjusted to 2.5 mg every other day.

If a dose is missed, instructions advise taking it as soon as it is remembered unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped; doses should not be doubled.

Research evidence / Overview of Studies for Femozol

The research base for Femozol (Letrozole) is primarily comprised of official, large-scale, international clinical trials, with studies focused on specific types of hormone-receptor positive breast cancer. Research describes group patterns and helps contextualize what has been observed so far, but does not determine whether an individual will respond similarly.

Evidence from Clinical Trials for Initial Adjuvant Treatment

In this context, Femozol was studied for its use following initial definitive treatment. The primary measurement research examined was Disease-Free Survival (DFS), which tracked the time elapsed until recurrence, secondary malignancy, or death. The findings describe patterns observed in the studies where the group receiving Femozol data show a differential pattern in Disease-Free Survival measurements compared to the group receiving the comparator. However, in initial and intermediate follow-up reports, the studies report how symptoms evolved in the observed populations and observed that differences in Overall Survival (OS) between the treatment groups were not consistently demonstrated. The long-term effects on Overall Survival are not fully established.

Evidence from Trials for Extended Adjuvant Treatment

Femozol was evaluated in women who had completed prior hormone treatment. The main focus of this research was studied for measures such as Disease-Free Survival. The clinical reports data show patterns related to Disease-Free Survival measurements when comparing the group receiving Femozol during the extension period to the placebo group. The impact on Overall Survival in the extended setting may be difficult to assess because patients in the placebo arm can often cross over to receive active treatments.

Evidence from Trials for Advanced or Metastatic Disease

For advanced disease, the main outcome studies monitored was Progression-Free Survival (PFS) and the Objective Response Rate (ORR). The research data show patterns related to Progression-Free Survival measurements when comparing the group receiving Femozol to groups receiving certain other endocrine therapies. Studies report how symptoms evolved in the observed populations and recorded the Objective Response Rate. The long-term effects are not fully established regarding Overall Survival.

Areas of Research Uncertainty

There is limited information for long-term outcomes regarding the final impact on Overall Survival. The evidence quality varies across studies when moving away from the definitive, large-scale Randomized Controlled Trials. The observation in this metric may be complicated due to patients receiving a variety of subsequent therapies after their trial treatment concludes. Overall, evidence highlights what is known — and what is still uncertain — about the full scope of treatment outcomes.

Key Studies & References

1. Ten-year update: NRG Oncology/NSABP B-42 randomized trial: Extended letrozole therapy in early-stage breast cancer
2. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A multicentre, open-label, randomised, phase 3 trial (GIM4 Trial Final Analysis)
3. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate (Second-line treatment)

How to Store and Dispose of Femozol

Femozol (letrozole) must be stored under specific regulatory conditions to maintain its stability and effectiveness. The tablets should be kept at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with protection from moisture and direct sunlight. It is required to keep the medicine in its original, closed container and strictly out of the sight and reach of children.

Disposal Requirements

Unused or expired Femozol should be discarded using an authorized drug take-back program. If this option is unavailable, the tablets can be mixed with an undesirable substance (such as used coffee grounds or dirt), sealed in a plastic bag, and placed in the household trash. The medication must never be flushed down the toilet or poured into any drain.